Form 4: Revolution Medicines CEO Sells Shares for Tax

Revolution Medicines' CEO, Mark A. Goldsmith, sold 12,871 shares of common stock for tax withholding obligations under a pre-arranged 10b5-1 plan.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc., sold 12,871 shares of common stock.
• The transaction occurred on March 17, 2026, at a price of $99.4804 per share.
• The sale was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following the reported transaction, Mr. Goldsmith directly beneficially owns 276,698 shares, which includes 201,150 RSUs.
• Mr. Goldsmith also indirectly beneficially owns 594,060 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, 64,424 shares through the Jonathan Goldsmith Revocable Trust, and 64,424 shares through the Rebecca Goldsmith Revocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is for a routine tax obligation under a pre-arranged plan, not indicative of a change in management's confidence or company fundamentals.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to insider trading and reducing concerns about opportunistic selling.
• The sale was explicitly for tax withholding obligations upon RSU vesting, which is a common and expected reason for insider sales and not indicative of a lack of confidence in the company.

Negatives

• A sale of shares by a high-ranking executive, even for tax purposes, reduces their direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes upon RSU vesting are a routine occurrence across all industries, particularly in high-growth sectors like biotechnology where equity compensation is prevalent. This transaction does not suggest any specific industry trend or competitive shift.

Comparison to Industry Standards

• This type of insider transaction, specifically for tax withholding related to RSU vesting, is a standard practice across publicly traded companies, including peers in the biotechnology sector such as Moderna (MRNA) or BioNTech (BNTX), where executives frequently sell a portion of vested equity to cover tax liabilities.
• The volume of shares sold (12,871) relative to the executive's total holdings (nearly 1 million shares) is not unusually large for such a purpose.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is for a routine tax purpose and represents a small fraction of the executive's total holdings.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

The transaction is a routine insider sale for tax withholding purposes under a pre-arranged plan, not signaling any fundamental change in the company's prospects. It does not provide new information that would warrant a change in investment strategy.

Keywords

Revolution Medicines, RVMD, Mark A. Goldsmith, Insider Trading, SEC Form 4, Stock Sale, 10b5-1 Plan, Restricted Stock Units, RSU Vesting, Tax Withholding